Therapeutic developments in pancreatic cancer

Z. Ian Hu, Eileen M. O’Reilly

Research output: Contribution to journalReview articlepeer-review

8 Scopus citations

Abstract

Pancreatic ductal adenocarcinoma (PDAC) has a rising incidence and is one of the most lethal human malignancies. Much is known regarding the biology and pathophysiology of PDAC, but translating this knowledge to the clinic to improve patient outcomes has been challenging. In this Review, we discuss advances and practice-changing trials for PDAC. We briefly review therapeutic failures as well as ongoing research to refine the standard of care, including novel biomarkers and clinical trial designs. In addition, we highlight contemporary areas of research, including poly(ADP-ribose) polymerase inhibitors, KRAS-targeted therapies and immunotherapies. Finally, we discuss the future of pancreatic cancer research and areas for improvement in the next decade.

Original languageEnglish (US)
Pages (from-to)7-24
Number of pages18
JournalNature Reviews Gastroenterology and Hepatology
Volume21
Issue number1
DOIs
StatePublished - Jan 2024

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Fingerprint

Dive into the research topics of 'Therapeutic developments in pancreatic cancer'. Together they form a unique fingerprint.

Cite this